

# Dimeric Benzodiazepines as Peptide Mimetics To Overcome p53-dependent Drug Resistance of Tumors

Elżbieta Speina <sup>1</sup>, Marcin Wilczek <sup>2</sup>, Adam Mieczkowski <sup>1,\*</sup>

<sup>1</sup> Institute of Biochemistry and Biophysics Polish Academy of Sciences 5a, Pawinskiego 5a, 02-106 Warsaw, Poland

<sup>2</sup> Department of Chemistry, University of Warsaw, Pasteura 1, 02-093, Warsaw, Poland

\* Correspondence: amiecz@ibb.waw.pl




Figure S1. HRMS spectrum of 10.




Figure S2. HRMS spectrum of 11.




Figure S3. <sup>1</sup>H NMR spectrum of 10.




Figure S4.  $^{13}\text{C}$  NMR spectrum of 10.




Figure S5. Dept135 NMR spectrum of 10.




Figure S6.  $^1\text{H}$  NMR spectrum of **11**.




Figure S7.  $^{13}\text{C}$  NMR spectrum of 11.





Figure S8. Dept135 NMR spectrum of 11.



**Figure S9.** Confluence measured by IncuCyte live-cell imaging in wild-type (HCT116) and p53 null mutant (HCT116p53<sup>-/-</sup>) cell lines treated with 40 μM **10**, **11**, cisplatin (cis-pl) or dimethyl sulfoxide (DMSO), used as a negative control. Representative images showing confluence (in blue) at 0, 24, 48 and 72 h with or without a drug are shown. UN, untreated cells. Yellow scale bars on images in the lower left corner represent 400 μm.